메뉴 건너뛰기




Volumn 89, Issue 3, 2016, Pages 537-538

Eculizumab in children with hemolytic uremic syndrome

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB;

EID: 84964533992     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2015.12.039     Document Type: Note
Times cited : (4)

References (8)
  • 2
    • 84878589219 scopus 로고    scopus 로고
    • Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome
    • C.M. Legendre, C. Licht, P. Muus, and et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome N Engl J Med 368 2013 2169 2181
    • (2013) N Engl J Med , vol.368 , pp. 2169-2181
    • Legendre, C.M.1    Licht, C.2    Muus, P.3
  • 3
    • 84964561130 scopus 로고    scopus 로고
    • Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
    • L.A. Greenbaum, M. Fila, G. Ardissino, and et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome Kidney Int 89 2016 701 711
    • (2016) Kidney Int , vol.89 , pp. 701-711
    • Greenbaum, L.A.1    Fila, M.2    Ardissino, G.3
  • 4
    • 84878608990 scopus 로고    scopus 로고
    • Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome
    • M. Lemaire, V. Fremeaux-Bacchi, F. Schaefer, and et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome Nat Genet 45 2013 531 536
    • (2013) Nat Genet , vol.45 , pp. 531-536
    • Lemaire, M.1    Fremeaux-Bacchi, V.2    Schaefer, F.3
  • 5
    • 84964480157 scopus 로고    scopus 로고
    • A national specialised service in England for atypical haemolytic uraemic syndrome - The first year's experience
    • N.S. Sheerin, D. Kavanagh, T.H. Goodship, and S. Johnson A national specialised service in England for atypical haemolytic uraemic syndrome - the first year's experience QJM 109 2016 27 33
    • (2016) QJM , vol.109 , pp. 27-33
    • Sheerin, N.S.1    Kavanagh, D.2    Goodship, T.H.3    Johnson, S.4
  • 6
    • 84937413194 scopus 로고    scopus 로고
    • Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: An update
    • G. Ardissino, I. Possenti, F. Tel, and et al. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update Am J Kidney Dis 66 2015 172 173
    • (2015) Am J Kidney Dis , vol.66 , pp. 172-173
    • Ardissino, G.1    Possenti, I.2    Tel, F.3
  • 7
    • 84954468656 scopus 로고    scopus 로고
    • The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies
    • E.H. Phillips, J.P. Westwood, V. Brocklebank, and et al. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies J Thromb Haemost 14 2016 175 185
    • (2016) J Thromb Haemost , vol.14 , pp. 175-185
    • Phillips, E.H.1    Westwood, J.P.2    Brocklebank, V.3
  • 8
    • 84960378679 scopus 로고    scopus 로고
    • The genetic fingerprint of susceptibility for transplant associated thrombotic microangiopathy [e-pub ahead of print]
    • November 2015. pii: blood-2015-08-663435
    • Jodele S, Zhang K, Zou F, et al. The genetic fingerprint of susceptibility for transplant associated thrombotic microangiopathy [e-pub ahead of print]. Blood. 24 November 2015. pii: blood-2015-08-663435, http://dx.doi.org/10.1182/blood-2015-08-663435.
    • Blood , vol.24
    • Jodele, S.1    Zhang, K.2    Zou, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.